NeuroSigma, Inc.

NeuroSigma, Inc. is a Los Angeles-based bioelectronics company developing non-invasive external trigeminal nerve stimulation (eTNS) technology for neurological and neuropsychiatric disorders. The company's flagship product, the Monarch eTNS® System, is the first FDA-cleared medical device for treating pediatric ADHD (ages 7–12) without surgery, implants, or medication. The Monarch system delivers gentle, precisely targeted electrical pulses to stimulate the trigeminal nerve—a key pathway influencing brain function, mood, and attention—for use during sleep under caregiver supervision. NeuroSigma's technology is supported by 10 clinical trials, 2,500+ patient treatments, and 50+ issued patents. The company targets multi-billion-dollar markets addressing unmet needs in autism spectrum disorder (ASD), epilepsy, depression, and other chronic neurological conditions. NeuroSigma combines clinical evidence with neuroengineering innovation to make evidence-based neuromodulation accessible and transformative for patients worldwide.